S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.45
+1.77
+10.61%
LENZ · LENZ Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
LENZ Therapeutics Inc (LENZ)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$3.23
+0.04
(+1.10%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$3.23
$3.15
$3.37
52-WEEK RANGE
$3.23
$3.12
$36.43
What's happening
- LENZ is up 1.10% today, trading at $3.23. — Live quote
- It's trading within 3% of its 52-week low ($3.12). (Finnhub fundamentals)
- Volume today (64,609) is well below its 3-month average of 849,990. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.02 actual vs. $-1.10 estimated (+7.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 5
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
LENZ
-79.88%
vs S&P 500
-93.24%
1-YEAR RETURN
LENZ
-90.41%
vs S&P 500
-105.57%
6-MONTH RETURN
LENZ
-68.37%
3-MONTH RETURN
LENZ
-39.70%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.02
Est. $-1.10
BEAT +7.0%
2026-04-26 (Q1 2026)
$-1.32
Est. $-1.09
MISS -21.0%
2026-01-26 (Q4 2025)
$-1.16
Est. $-0.99
MISS -17.1%
2025-10-26 (Q3 2025)
$-0.59
Est. $-0.72
BEAT +18.1%
Valuation Measures & Ratios
Enterprise Value4$77.0M
Forward P/E5—
PEG Ratio6-0.01
Price / Sales (TTM1)4.71
Price / Book70.81
EV4 / Revenue8.58
EV4 / EBITDA—
Profit Margin-586.74%
Operating Margin-631.70%
Return on Equity (ROE8)-43.72%
Return on Assets (ROA9)-40.23%
Avg Volume (3M)849,990
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $177.4M | $287.4M | $1.32B | $822.1M | $707.1M |
| P/E | -1.69 | -3.28 | -23.33 | -16.44 | -13.67 |
| Price/Book | 0.81 | 1.17 | 6.79 | 3.98 | 3.68 |
| EV/EBITDA | -1.35 | -2.72 | -19.74 | — | — |
| ROE | -47.90% | -35.59% | -29.11% | -24.23% | -26.94% |
| ROA | -44.39% | -32.19% | -26.79% | -23.01% | -25.71% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short10,560,869
Change from Prior Settlement-0.65%
% of Float—
Days to Cover (Short Ratio)13.78
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 9.7% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 10-Q, filed 2026-08-11; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -586.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -90.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on LENZ
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.5M | $1.9M | — | $5.0M | $0 | — | — | — |
| Operating income | -$34.2M | -$44.1M | -$18.9M | -$16.9M | -$16.9M | -$12.9M | -$14.4M | -$16.1M |
| Net income | -$31.9M | -$41.5M | -$16.7M | -$14.9M | -$14.6M | -$10.2M | -$10.3M | -$16.6M |
| EPS (diluted) | $-1.02 | $-1.32 | $-0.59 | $-0.53 | $-0.53 | $-0.38 | $-0.40 | $-3.53 |
| EPS (basic) | $-1.02 | $-1.32 | $-0.59 | $-0.53 | $-0.53 | $-0.38 | $-0.40 | $-3.53 |
| Operating margin | -$623 | -$2.3K | — | -$337 | — | — | — | — |
| Net margin | -$582 | -$2.2K | — | -$298 | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $236.6M | $272.5M | $305.9M | $210.7M | $217.3M | $201.3M | $215.3M | $224.0M |
| Total liabilities | $17.3M | $26.0M | $21.5M | $16.8M | $11.0M | $9.2M | $11.2M | $8.7M |
| Stockholders' equity | $219.3M | $246.5M | $284.3M | $193.9M | $206.4M | $192.0M | $204.1M | $215.3M |
| Total current assets | $233.3M | $268.4M | $301.4M | $207.0M | $213.6M | $197.9M | $211.9M | $220.7M |
| Total current liabilities | $17.2M | $25.8M | $21.2M | $16.3M | $10.4M | $8.6M | $10.4M | $7.7M |
| Cash & equivalents | $24.2M | $24.8M | $25.2M | $25.4M | $37.6M | $23.0M | $20.2M | $41.0M |
| Accounts receivable | $442.0K | $343.0K | $329.0K | — | — | — | $0 | — |
| Inventory | $4.1M | $3.5M | $2.9M | $949.0K | — | — | $0 | — |
| Property, plant & equipment | $1.0M | $1.1M | $1.2M | $1.3M | $1.2M | $926.0K | $651.0K | $372.0K |
| Other non-current assets | $1.8M | $2.5M | $2.5M | $1.6M | $1.6M | $1.4M | $1.4M | $1.4M |
| Accounts payable | $6.6M | $10.9M | $4.2M | $4.3M | $2.9M | $3.7M | $4.3M | $2.8M |
| Accrued liabilities | $9.8M | $14.9M | $17.0M | $12.0M | $7.5M | $4.9M | $6.1M | $4.9M |
| Deferred revenue (current) | $785.0K | — | $0 | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | $0 | $64.0K |
| Common stock & paid-in capital | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $0 |
| Retained earnings | -$300.5M | -$268.6M | -$227.1M | -$191.2M | -$174.5M | -$159.6M | -$145.0M | -$132.4M |
| Accumulated other comprehensive income (loss) | -$629.0K | -$450.0K | $242.0K | $227.0K | $38.0K | $123.0K | $196.0K | $523.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.7M | -$33.6M | -$33.0M | -$8.6M | -$11.5M | -$16.0M | -$9.1M | -$10.6M |
| Investing cash flow | $37.8M | $33.2M | -$89.8M | -$4.3M | -$414.0K | $18.9M | -$11.9M | -$62.2M |
| Financing cash flow | $395.0K | $14.0K | $122.6M | $598.0K | $26.5M | $44.0K | $53.0K | $29.8M |
| Free cash flow | -$38.7M | -$33.6M | -$33.1M | -$9.0M | -$11.7M | -$16.2M | -$9.2M | -$10.8M |
| Capital expenditures | $16.0K | $18.0K | $38.0K | $439.0K | $240.0K | $110.0K | $149.0K | $186.0K |
| Depreciation & amortization | $110.0K | $111.0K | $107.0K | $125.0K | $19.0K | $36.0K | $25.0K | $10.0K |
| Share-based compensation | $4.5M | $4.3M | $3.7M | $3.5M | $2.8M | $2.6M | $1.6M | $2.2M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | $99.0K | $14.0K | $329.0K | — | $0 | $0 | $0 | — |
| Change in inventory | -$19.0K | $889.0K | $3.3M | $949.0K | $0 | $0 | $0 | $0 |
| Change in accounts payable | -$4.3M | $6.8M | -$156.0K | $1.7M | -$857.0K | -$771.0K | $1.3M | -$1.6M |
| Purchases of investments | $7.4M | $16.1M | $133.1M | $56.3M | $58.3M | $33.1M | $46.6M | $84.0M |
| Sales/maturities of investments | $45.1M | $49.2M | $43.3M | $52.4M | $58.1M | $52.1M | $34.9M | $22.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $19.1M | $0 | — | — | — |
| Operating income | -$91.1M | -$58.6M | -$72.4M | -$105.6M | -$60.4M |
| Net income | -$82.1M | -$49.8M | -$70.0M | -$101.1M | -$70.8M |
| EPS (diluted) | $-2.85 | $-2.34 | $-35.71 | $-1.84 | $-2.45 |
| EPS (basic) | $-2.85 | $-2.34 | $-35.71 | $-1.84 | $-2.45 |
| Operating margin | -$477 | — | — | — | — |
| Net margin | -$430 | — | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $305.9M | $215.3M | $70.4M | $321.9M | $402.0M |
| Total liabilities | $21.5M | $11.2M | $19.7M | $25.6M | $17.9M |
| Stockholders' equity | $284.3M | $204.1M | -$92.7M | -$24.2M | $384.1M |
| Total current assets | $301.4M | $211.9M | $67.2M | $275.4M | $381.7M |
| Total current liabilities | $21.2M | $10.4M | $18.5M | $13.0M | $12.1M |
| Cash & equivalents | $25.2M | $20.2M | $35.1M | $47.7M | $377.0M |
| Accounts receivable | $329.0K | $0 | — | — | — |
| Inventory | $2.9M | $0 | — | — | — |
| Property, plant & equipment | $1.2M | $651.0K | $54.0K | $22.6M | $6.5M |
| Other non-current assets | $2.5M | $1.4M | $21.0K | $1.3M | $454.0K |
| Accounts payable | $4.2M | $4.3M | $5.7M | $2.6M | $2.5M |
| Accrued liabilities | $17.0M | $6.1M | $12.8M | — | — |
| Other non-current liabilities | — | $0 | $121.0K | $10.8M | $0 |
| Common stock & paid-in capital | $1.0K | $1.0K | $10.0K | $1.0K | $1.0K |
| Retained earnings | -$227.1M | -$145.0M | -$95.2M | -$242.4M | -$141.4M |
| Accumulated other comprehensive income (loss) | $242.0K | $196.0K | $6.0K | -$1.0M | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$69.2M | -$59.4M | -$60.4M | -$88.0M | -$52.9M |
| Investing cash flow | -$75.7M | -$154.5M | -$29.6M | -$241.9M | -$5.7M |
| Financing cash flow | $149.7M | $199.0M | $80.7M | $597.0K | $417.5M |
| Free cash flow | -$70.0M | -$59.9M | -$60.4M | -$94.6M | -$58.6M |
| Capital expenditures | $827.0K | $468.0K | $30.0K | $6.6M | $5.7M |
| Depreciation & amortization | $287.0K | $58.0K | $15.0K | — | — |
| Share-based compensation | $12.5M | $6.4M | $1.3M | $13.5M | $7.9M |
| Deferred income taxes | $0 | $0 | $0 | — | — |
| Change in accounts receivable | $329.0K | $0 | — | — | — |
| Change in inventory | $4.3M | $0 | — | — | — |
| Change in accounts payable | -$90.0K | -$4.3M | $856.0K | $194.0K | $1.8M |
| Purchases of investments | $280.8M | $241.9M | $52.1M | — | — |
| Sales/maturities of investments | $206.0M | $87.9M | $22.5M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding LENZ as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-10 to 2026-03-27
Recent transactions
- Most recent: George Jeffrey P. (Director) — Open market purchase of 5,592 shares on 2026-03-27.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| George Jeffrey P. | Director | Open market purchase | 2026-03-27 | 5,592 |
| Schimmelpennink Evert B. | President, CEO and Secretary | Open market purchase | 2026-03-27 | 28,089 |
| Chevallard Daniel R. | Chief Financial Officer | Open market purchase | 2026-03-27 | 7,500 |
| Olsson Shawn | Chief Commercial Officer | Option exercise | 2025-11-17 | 10,000 |
| MCCOLLUM JAMES W | Director | Open market purchase | 2025-11-07 | 10,500 |
| Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 2025-09-30 | 49,701 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-03-27 | George Jeffrey P. | Director | Open market purchase | 5,592 | $8.92 |
| 2026-03-27 | Schimmelpennink Evert B. | President, CEO and Secretary | Open market purchase | 28,089 | $8.95 |
| 2026-03-27 | Chevallard Daniel R. | Chief Financial Officer | Open market purchase | 7,500 | $8.57 |
| 2025-11-17 | Olsson Shawn | Chief Commercial Officer | Option exercise | 10,000 | $2.08 |
| 2025-11-17 | Olsson Shawn | Chief Commercial Officer | Open market sale | 4,212 | $25.74 |
| 2025-11-17 | Olsson Shawn | Chief Commercial Officer | Open market sale | 5,788 | $26.37 |
| 2025-11-07 | MCCOLLUM JAMES W | Director | Open market purchase | 10,500 | $22.79 |
| 2025-11-07 | Chevallard Daniel R. | Chief Financial Officer | Open market purchase | 20 | $22.71 |
| 2025-11-07 | Chevallard Daniel R. | Chief Financial Officer | Open market purchase | 2,178 | $22.76 |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 49,701 | $45.35 |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 34,405 | $45.35 |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 83,066 | $46.41 |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 57,502 | $46.41 |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 177 | $47.01 |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 123 | $47.01 |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 49,479 | $41.59 |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 24,370 | $41.59 |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 40,907 | $43.00 |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 20,148 | $43.00 |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 268 | $43.30 |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 132 | $43.30 |
| 2025-08-26 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 43,978 | $38.97 |
| 2025-08-26 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 21,661 | $38.97 |
| 2025-08-26 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 3,465 | $39.50 |
| 2025-08-26 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 1,707 | $39.50 |
| 2025-08-25 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 50,270 | $39.53 |
| 2025-08-25 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 24,760 | $39.53 |
| 2025-08-25 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 2,149 | $39.92 |
| 2025-08-25 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 1,058 | $39.92 |
| 2025-08-22 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 20,493 | $40.03 |
| 2025-08-22 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 10,076 | $40.03 |
| 2025-08-22 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 5,668 | $40.59 |
| 2025-08-22 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 2,809 | $40.59 |
| 2025-08-18 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 30,628 | $38.56 |
| 2025-08-18 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 15,085 | $38.56 |
| 2025-08-15 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 145,051 | $39.50 |
| 2025-08-15 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 69,949 | $39.50 |
| 2025-07-10 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 191,376 | $34.00 |
| 2025-06-27 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 200,000 | $30.46 |
| 2025-06-20 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 100,877 | $30.35 |
| 2025-06-20 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 133,924 | $30.25 |
| 2025-06-18 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 100,000 | $29.95 |
| 2025-06-10 | Versant Venture Capital VI, L.P. | Reporting person | Open market sale | 350,000 | $29.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:37 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-06-30 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-15 | View on SEC.gov → |
| 2026-06-12 | 8-K | 2026-06-12 | View on SEC.gov → |
| 2026-05-11 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about LENZ (LENZ Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Millennium Management Reveals 3.7% Stake in LENZ Therapeutics via Schedule 13G Amendment
Kalkine Media · 2026-10-21 -
TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $50
Benzinga · 2026-10-21 -
LENZ Therapeutics (LENZ) Stock Fair Value Falls After Analysts Cut VIZZ Launch Expectations
Yahoo · 2026-10-21 -
Bethany Joy Lenz shares her six favorite books
Page Six · 2026-10-20 -
MTU names Susanne Lenz: MTU Aero Engines stock falls 1.08 percent
AD HOC NEWS · 2026-10-20 -
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5
Benzinga · 2026-10-19 -
LENZ Nov 2026 7.500 put (LENZ261120P00007500) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-18 -
LENZ Nov 2026 7.500 put (LENZ261120P00007500) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-18
No headlines in this category right now — try “All”.